PlainPharmaWatch

CMS Open Payments · Program Year 2024

NuMED for Children, LLC

NuMED for Children, LLC reported $120,000.00 across General Payments, Research, and Ownership to 4 physicians and teaching hospitals across 4 transactions.

$120.0K
All-tracks total
4
Transactions
4
Recipients
−$4.2K
General Payments vs PY2023

NuMED for Children, LLC reported $120,000.00 across all CMS Open Payments tracks (General + Research + Ownership) to 4 physicians and teaching hospitals in Program Year 2024 - ranking #1137 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $120,000.00, averaging $30.0K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer numed-for-children-llc NuMED for Children, LLC

$120.0K · #1137/1,925 · 0.0% industry · PY2024

  • TOT $120.0K
  • RANK #1137
  • SHARE 0.0%
  • TXN 4
  • RCP 4
  • CAT 1
  • GEN $120.0K
  • ΔGEN −$4.2K
  • TOP1 25.0%
  • PY 2024

Nearest volume peer: Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ($120.0K)

Shalby Advanced Technologies…$120.5KCorMedix Inc.$120.2KAurobindo Pharma USA, Inc.$120.1KNovartis Gene Therapies, Inc…$120.0KNuMED for Children, LLC (thi…$120.0K
All-tracks payment totals near NuMED for Children, LLC (CMS Open Payments PY2024)

NuMED for Children, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

NuMED for Children, LLC's CMS-reported General Payments decreased by $4.2K (−3.4%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NUMED FOR CHILDREN, LLCPY2023: NUMED FOR CHILDREN, LLCPY2024: NuMED for Children, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$124.2KPY2024$120.0K
PY2023
$124,188.42
PY2024
$120,000.00

What the Data Shows for NuMED for Children, LLC

Rank #1137 of 1,925 companies in CMS Open Payments for 2024 belongs to NuMED for Children, LLC, which reported $120,000.00 across 4 transactions to 4 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $30.0K per transaction and $30.0K per recipient.

4 transactions worth $120.0K make "Consulting Fee" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 1 types of general payments, NuMED for Children, LLC's largest category was "Consulting Fee" at $120.0K - 100.0% of General Payments.

How NuMED for Children, LLC divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$120.0K
Payment Type Amount Transactions
Consulting Fee $120.0K 4

Recipient Concentration in General Payments

The five largest recipient relationships account for $120,000.00 (100.0%) of $120,000.00 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for NuMED for Children, LLC

The five named recipients with the highest reported General Payments from this company

Charles E Mullins$30.0KZiyad M Hijazi$30.0KJohn Patrick Cheatham$30.0KGareth J Morgan$30.0K
  1. 1

    Charles E Mullins

    $30,000.00 across 1 reported transactions

  2. 2

    Ziyad M Hijazi

    $30,000.00 across 1 reported transactions

  3. 3

    John Patrick Cheatham

    $30,000.00 across 1 reported transactions

  4. 4

    Gareth J Morgan

    $30,000.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as NuMED for Children, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about NuMED for Children, LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with NuMED for Children, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download NuMED for Children, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.